MENU
+Compare
JDOC
ETF ticker: NASDAQ
AS OF
Feb 3, 10:30 AM (EDT)
Price
$58.89
Change
+$4.64 (+8.55%)
Net Assets
8.8M

JDOC stock forecast, quote, news & analysis

The investment seeks to provide long-term capital appreciation... Show more

Category: #Health
JDOC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for JDOC with price predictions
Feb 03, 2026

Momentum Indicator for JDOC turns negative, indicating new downward trend

JDOC saw its Momentum Indicator move below the 0 level on January 28, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator turned negative. In of the 34 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for JDOC moved out of overbought territory on January 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 25 cases where JDOC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for JDOC turned negative on January 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JDOC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

JDOC broke above its upper Bollinger Band on January 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JDOC advanced for three days, in of 95 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 128 cases where JDOC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Medtronic plc (NYSE:MDT).

Industry description

The investment seeks to provide long-term capital appreciation. The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.

Market Cap

The average market capitalization across the JPMorgan Healthcare Leaders ETF ETF is 89.1B. The market cap for tickers in the group ranges from 1.51B to 898.12B. LLY holds the highest valuation in this group at 898.12B. The lowest valued company is BHVN at 1.51B.

High and low price notable news

The average weekly price growth across all stocks in the JPMorgan Healthcare Leaders ETF ETF was -1%. For the same ETF, the average monthly price growth was 1%, and the average quarterly price growth was 21%. AZN experienced the highest price growth at 93%, while IQV experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the JPMorgan Healthcare Leaders ETF ETF was 1%. For the same stocks of the ETF, the average monthly volume growth was 107% and the average quarterly volume growth was 22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 62
Price Growth Rating: 47
SMR Rating: 62
Profit Risk Rating: 67
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
JDOC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
J.P. Morgan Exchange-Traded Fund Trust270 Park AvenueNew York
Phone
(800) 480-4111
Web
N/A